These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 15166624)

  • 1. Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences.
    Fazeny-Dörner B; Mader RM; Piribauer M; Rizovski B; Stögermaier B; Marosi C
    Anticancer Drugs; 2004 Jun; 15(5):495-8. PubMed ID: 15166624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme.
    Fazeny-Dörner B; Veitl M; Wenzel C; Rössler K; Ungersböck K; Dieckmann K; Piribauer M; Hainfellner J; Marosi C
    Br J Cancer; 2003 Feb; 88(4):496-501. PubMed ID: 12592361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme.
    Fazeny-Dörner B; Veitl M; Wenzel C; Piribauer M; Rössler K; Dieckmann K; Ungersböck K; Marosi C
    Anticancer Drugs; 2003 Jul; 14(6):437-42. PubMed ID: 12853885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study of the clinical pharmacokinetics of fotemustine in various tumor indications].
    Lokiec F; Beerblock K; Deloffre P; Lucas C; Bizzari JP
    Bull Cancer; 1989; 76(10):1063-9. PubMed ID: 2635634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme.
    De Felice F; Bulzonetti N; Musio D; D'Elia A; Salvati M; Tombolini V
    Anticancer Res; 2013 Sep; 33(9):4013-6. PubMed ID: 24023343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment and other combination regimens.
    Bajetta E; Del Vecchio M; Bajetta R; Canova S
    Tumori; 2007; 93(3):suppl 22-6. PubMed ID: 17679485
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical significance of mustoforan in management of malignant glioma].
    Kobiakov GL
    Vopr Onkol; 2007; 53(6):724-9. PubMed ID: 18416147
    [No Abstract]   [Full Text] [Related]  

  • 8. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
    Beauchesne PD; Taillandier L; Bernier V; Carnin C
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas.
    Tranchand B; Lucas C; Biron P; Giroux B; Gordon B; Richards R; Solere P; Roux N; Evene E; Mornex F
    Cancer Chemother Pharmacol; 1993; 32(1):46-52. PubMed ID: 8462123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
    Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
    J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation.
    Petrović IM; Korićanac LB; Todorović DV; Ristić-Fira AM; Valastro LM; Privitera G; Cuttone G
    Ann N Y Acad Sci; 2007 Jan; 1095():154-64. PubMed ID: 17404028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
    Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.
    Gerard B; Aamdal S; Lee SM; Leyvraz S; Lucas C; D'Incalci M; Bizzari JP
    Eur J Cancer; 1993; 29A(5):711-9. PubMed ID: 8471329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo.
    Stamatakos GS; Antipas VP; Uzunoglu NK
    Comput Biol Med; 2006 Nov; 36(11):1216-34. PubMed ID: 16207487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic intra-arterial infusion of fotemustine: pharmacokinetics.
    Fety R; Lucas C; Solere P; Cour V; Vignoud J
    Cancer Chemother Pharmacol; 1992; 31(2):118-22. PubMed ID: 1451232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study.
    Iliadis A; Launay-Iliadis MC; Lucas C; Fety R; Lokiec F; Tranchand B; Milano G
    Eur J Cancer; 1996 Mar; 32A(3):455-60. PubMed ID: 8814692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comments on: Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine, Seeber, et al., Eur J Cancer 1998, 34, 2129-2131.
    Comella P; Daponte A
    Eur J Cancer; 1999 Jul; 35(7):1163-4. PubMed ID: 10533465
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
    Diez BD; Statkevich P; Zhu Y; Abutarif MA; Xuan F; Kantesaria B; Cutler D; Cantillon M; Schwarz M; Pallotta MG; Ottaviano FH
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):727-34. PubMed ID: 19641919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic profile of fotemustine in rat plasma by electrochemical detection.
    Bartosek I; Corada M; Dallarda S; Lucas C; Deloffre P; Guaitani A
    Xenobiotica; 1991 Feb; 21(2):235-42. PubMed ID: 2058178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma.
    Joukhadar C; Klein N; Mader RM; Schrolnberger C; Rizovski B; Heere-Ress E; Pehamberger H; Strauchmann N; Jansen B; Müller M
    Cancer; 2001 Oct; 92(8):2190-6. PubMed ID: 11596037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.